Product Information
RIVASTIGMINE 3 MG CAPSULE is a generic product labeled by Dr. Reddy's Laboratories Inc., priced at $0.1458 per EA under NDC 55111035360. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Oct 31, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
3 mg/1
Manufacturer
Dr. Reddy's Laboratories Inc.NDC
55111035360
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RIVASTIGMINE TARTRATEApproval Type
Generic (ANDA)
FDA Application
ANDA077130FDA Approved
10/31/2007
TE Code
AB
On Market Since
9/1/2011
Pharmacological Classes
Price Statistics
The NADAC for RIVASTIGMINE 3 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 91.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1458 per EA |
|---|---|
| All-time high | $1.8210 (Feb 12, 2014) |
| All-time low | $0.1451 (Jul 17, 2024) |
| 52-week high | $0.1853 |
| 52-week low | $0.1458 |
| Median price | $0.3352 |
| Average price | $0.6184 |
| Largest weekly change | -37.0% (Sep 20, 2017) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Dr. Reddy's Laboratories Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Rivastigmine Tartrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinesterase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIVASTIGMINE 3 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for RIVASTIGMINE 3 MG CAPSULE, manufactured by Dr. Reddy's Laboratories Inc., is $0.1458 per EA (NDC 55111035360), effective Sep 30, 2026.
How has the price of RIVASTIGMINE 3 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for RIVASTIGMINE 3 MG CAPSULE has declined 91.9%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for RIVASTIGMINE 3 MG CAPSULE?
Since Nov 28, 2013, the NADAC for RIVASTIGMINE 3 MG CAPSULE has ranged from a low of $0.1451 (Jul 17, 2024) to a high of $1.8210 (Feb 12, 2014), with a median of $0.3352 per EA.
Are there cheaper alternatives to RIVASTIGMINE 3 MG CAPSULE?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RIVASTIGMINE 3 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures RIVASTIGMINE 3 MG CAPSULE?
RIVASTIGMINE 3 MG CAPSULE (NDC 55111035360) is labeled by Dr. Reddy's Laboratories Inc., and CMS classifies it as a generic product.